Daily Endocrinology Research Analysis
Analyzed 100 papers and selected 3 impactful papers.
Summary
Top endocrine research today spans clinical, translational, and mechanistic advances. A phase 3 randomized trial shows once-weekly somapacitan is non-inferior to daily growth hormone for idiopathic short stature with similar safety and reduced treatment burden. Human clamp–MRI data redefine neurovascular–endocrine coupling in type 1 diabetes with impaired hypoglycemia awareness, while basic research links adipocyte circadian control of mitochondrial complex I to systemic metabolic homeostasis.
Research Themes
- Long-acting hormone therapies and adherence in pediatric endocrinology
- Neurovascular–endocrine coupling in hypoglycemia awareness
- Circadian–mitochondrial control of systemic metabolism
Selected Articles
1. Somapacitan in children with idiopathic short stature: a randomised controlled phase 3 study.
In a 52-week, randomized, open-label phase 3 trial across 20 countries (n=88), once-weekly somapacitan was non-inferior to daily GH for height velocity in children with idiopathic short stature (10.2 vs 10.6 cm/year; ETD -0.3 cm/year; NI confirmed). Safety profiles were similar with mostly mild AEs, and patient-reported measures favored lower treatment burden with weekly dosing.
Impact: This RCT provides high-quality evidence that a once-weekly long-acting GH maintains efficacy and safety while potentially improving adherence and quality of life in ISS, addressing a major treatment burden.
Clinical Implications: Once-weekly somapacitan could become a practical alternative to daily GH for ISS, with comparable growth outcomes and potentially better adherence. Longer-term extension data and real-world adherence, cost-effectiveness, and regulatory approvals will guide adoption.
Key Findings
- Height velocity at 52 weeks: 10.2 cm/year (somapacitan) vs 10.6 cm/year (daily GH); ETD -0.3 cm/year with NI confirmed.
- Similar safety profiles with predominantly mild AEs in both groups (events in ~79% of participants).
- Patient-reported disease/treatment burden favored once-weekly dosing.
Methodological Strengths
- Randomized, active-comparator, international phase 3 design with predefined non-inferiority.
- Included patient-reported outcomes assessing treatment burden.
Limitations
- Open-label design may introduce performance/reporting bias.
- Modest sample size and 52-week main phase; long-term efficacy/safety not fully characterized.
Future Directions: Report the 104-week extension, evaluate adherence and glycemic/metabolic safety longer-term, and conduct pragmatic and cost-effectiveness studies to support guideline integration.
OBJECTIVE: Daily growth hormone (GH) injections restore normal growth and improve psychological outcomes in children with idiopathic short stature (ISS) but treatment burden is significant. The objective of this study is to demonstrate efficacy and safety of once-weekly somapacitan, a long-acting GH, in children with ISS. DESIGN: REAL8 (ClinicalTrials.gov: NCT05330325) is a global, randomised, open-labelled, active-comparator, phase 3 basket study including four non-GH deficiency indications comprising a 52-week main phase and 104-week extension. Here, we present 52-week results from the REAL8 ISS study. METHODS: 88 pre-pubertal, treatment-naive children with ISS at clinics in 20 countries were randomised 2:1 to somapacitan 0.24 mg/kg/week or daily GH 0.050 mg/kg/day, both administered subcutaneously. 85 children completed the main 52-week treatment period. RESULTS: Observed mean height velocity, HV, (SD) at week 52 was 10.2 (1.7) and 10.6 (1.6) cm/year for somapacitan and daily GH groups, respectively (estimated treatment difference [ETD]: -0.3 cm/year [-1.00;0.42]95%CI, non-inferiority confirmed). Safety profiles were similar (somapacitan: 191 events in 47 (79.7%) participants, daily GH: 87 events in 22 (78.6%) participants) with most adverse events (AEs) mild and unlikely related to study product. Disease and treatment burden questionnaires presented favourable results. CONCLUSIONS: Similar efficacy and safety were confirmed for once-weekly somapacitan versus daily GH in treatment-naïve children with ISS, with favourable patient-reported outcome (PRO) measures, setting the ground for future treatment for ISS with a once-weekly option.
2. Disrupted Neurovascular-Endocrine Coupling in Type 1 Diabetes with impaired awareness of hypoglycaemia.
Using hyperinsulinemic stepped clamps with ASL-MRI, the study shows that T1D disrupts suppression of sympathetic-range CBF oscillations during hypoglycemia, and IAH further blunts thalamo-striatal/insula CBF responses. Hormone–CBF coupling patterns invert in NAH and become strongly positive in IAH for cortisol and epinephrine, defining a distinct neurovascular phenotype.
Impact: Integrating endocrine and neurovascular dynamics during hypoglycemia offers a mechanistic framework for impaired awareness in T1D and identifies potential imaging/physiologic biomarkers to guide interventions.
Clinical Implications: Physiologic/imaging markers of neurovascular–endocrine coupling may stratify risk and monitor therapies (e.g., hypoglycemia avoidance training, pharmacologic modulation of sympathetic tone) to restore awareness.
Key Findings
- Controls: robust hypoglycemia-evoked CBF increases in thalamo-striatal and salience networks (mean d≈0.93) and suppression of vasomotor CBF oscillations (d=0.71).
- T1D: preserved CBF increase but failure to attenuate sympathetic-range oscillations (effect vs controls d=0.43).
- IAH: further blunted CBF responses (NAH>IAH d=0.51) and altered hormone–CBF coupling (cortisol/epinephrine positive in controls, negative in NAH, strongly positive in IAH).
Methodological Strengths
- Gold-standard hyperinsulinemic stepped clamp with concurrent ASL-MRI for cerebral perfusion.
- Serial hormonal profiling enabling coupling analyses with CBF and vasomotor oscillations.
Limitations
- Non-randomized physiological study with moderate sample size; generalizability to broader T1D populations is uncertain.
- Cross-sectional design precludes causal inference on progression to impaired awareness.
Future Directions: Validate coupling biomarkers longitudinally, test interventions that modulate sympathetic tone or perfusion reserve, and assess whether restoring coupling improves awareness and reduces severe hypoglycemia.
Recurrent hypoglycaemia in type 1 diabetes (T1D) may culminate in impaired awareness of hypoglycaemia (IAH). While neuroimaging studies identified affected brain regions, more complex perspectives integrating vascular dynamics with endocrine profile are missing. 26 healthy adults, 30 T1D patients with normal hypoglycaemia awareness (NAH), and 25 T1D patients with IAH underwent a hyperinsulinaemic stepped clamp (euglycaemia → hypoglycaemia 50 mg.dL-1) combined with pseudo-continuous arterial spin-labelling MRI. Cerebral blood flow (CBF) and sympathetic vasomotor-range (0.02-0.05 Hz) CBF oscillations were modelled against serially sampled plasma cortisol, epinephrine, norepinephrine and glucagon. In healthy controls, hypoglycaemia evoked robust thalamo-striatal and salience-interoceptive CBF increases (mean Cohen's d across significant clusters=0.93) and suppression of vasomotor oscillations (d=0.71). T1D retained CBF response but failed to attenuate oscillations (dT1D>controls=0.43). IAH further blunted hypoglycaemia-associated CBF increase, especially in thalamus, striatum and insula (dNAH>IAH=0.51). Hormone-CBF coupling differed quantitatively: cortisol/epinephrine-CBF correlations were positive in controls (r=0.37/0.26), negative in NAH (-0.16/-0.40) and strongly positive in IAH (0.42/0.46). Thus, our findings indicate that T1D disrupts dynamic, sympathetic modulation of CBF, whereas IAH additionally impairs perfusion reserve and shows maladaptive catecholamine-dependent CBF regulation, suggesting a qualitatively distinct neurovascular phenotype.
3. Adipocyte NADH dehydrogenase reverses circadian and diet-induced metabolic syndrome.
Adipocyte circadian clocks maintain metabolic homeostasis by driving diurnal complex I respiration. Clock disruption (genetic or diet-induced) suppresses complex I, dampening PPAR and insulin signaling, whereas adipocyte NDI1 expression restores complex I function and reverses metabolic dysfunction independent of weight.
Impact: This study uncovers a clock-to-mitochondria axis in adipocytes that causally links circadian disruption to metabolic syndrome and demonstrates a precise mitochondrial rescue (NDI1) that normalizes systemic metabolism.
Clinical Implications: Targeting adipocyte mitochondrial complex I rhythms or their downstream pathways (PPAR/insulin signaling) may offer novel strategies for circadian- and diet-related metabolic diseases; biomarkers of clock–mitochondria coupling could enable patient stratification.
Key Findings
- Adipocyte clock disruption (genetic deletion or high-fat diet) reduces complex I respiration and suppresses PPAR and insulin signaling.
- Adipocyte-specific expression of yeast NDI1 restores complex I function and protects against circadian- and diet-induced metabolic dysfunction independent of weight.
- Establishes mitochondrial complex I as a clock-controlled regulator of systemic metabolic homeostasis.
Methodological Strengths
- Causal genetic manipulations with tissue-specific clock disruption and rescue via NDI1.
- Convergent phenotyping linking mitochondrial function to systemic metabolic outcomes.
Limitations
- Predominantly male mouse data; human validation is lacking.
- NDI1 is non-mammalian; translational path for clinical application requires alternative strategies.
Future Directions: Define human correlates of adipocyte clock–complex I coupling, explore pharmacologic/chrono-therapeutic modulation of complex I and PPAR/insulin pathways, and test tissue-specific mitochondrial enhancers.
Circadian clocks are internal timing systems that enable organisms to anticipate and adapt to daily environmental changes. These rhythms arise from a transcription-translation feedback loop in which CLOCK and BMAL1 regulate the expression of thousands of genes, including their repressors PER and CRY. Disruption of circadian rhythms contributes to obesity, metabolic disease and cancer, yet how the clock maintains metabolic homeostasis remains limited. Here we report that the clock regulates oxidative metabolism in adipocytes through diurnal complex I respiration. Disrupting the clock in male mice via adipocyte-specific genetic deletion or high-fat-diet feeding reduces complex I respiration in adipocytes, leading to suppression of the peroxisome proliferator-activated receptor and insulin signalling pathways. In contrast, restoring complex I function by expressing yeast NDI1 in adipocytes protects against diet-induced and circadian-induced metabolic dysfunction independently of weight gain. These findings reveal that adipocyte circadian disruption impairs metabolic health through mitochondrial complex I dysfunction, establishing clock control of complex I as a key regulator of metabolic homeostasis.